Chimeric antigen receptor(CAR) T-cell therapy is effective in relapsed/refractory large B-cell lymphoma(LBCL), but evidence in elderly patients(≥70y) is limited. We compared outcomes of tisagenlecleucel(tisa-cel) and axicabtagene ciloleucel(axi-cel) and assessed prognostic factors. We analyzed 1,191 patients(aged ≥70y) reported to the EBMT(tisa-cel n=402; axi-cel n=789). Median follow-up was 22.7 months. Outcomes included cytokine release syndrome(CRS), immune effector cell-associated neurotoxicity syndrome(ICANS), overall survival(OS), progression-free survival(PFS), relapse incidence(RI), and non-relapse mortality(NRM). Multivariable models adjusted for age, sex, ECOG, disease status, prior transplantation, and year of infusion. Median age at infusion was 74y; 65.6% were aged 70-75y. Progressive disease at infusion was 59% vs 53% for tisa-cel and axi-cel(p=0.04). Tisa-cel patients were older(74.0 vs 73.7y, p=0.019). At day-30, CRS(any grade) occurred in 62% vs 77%(p.
The clinical utility of routine monitoring of chimeric antigen receptor (CAR) T-cell expansion post-infusion remains controversial. We conducted a retrospective analysis of a prospectively collected cohort of 176 patients with relapsed/refractory large B-cell lymphoma (LBCL) treated with axicabtagene ciloleucel (axi-ce...
Brydon Panozzo, S. Robinson, A. Minson et al.· British Journal of Haematolo...· 0 citations
OBJECTIVES
Baseline systemic inflammation has emerged as a determinant of outcome after CD19-directed CAR-T therapy. We evaluated the prognostic performance of the recently developed INFLAmmation MIXture Model (InflaMix) in an independent bicentric cohort of patients with large B-cell lymphoma (LBCL) receiving commerci...
Eugenio Galli, D. Mannina, Alessandro Corrente et al.· European Journal of Haematol...· 0 citations
Penile squamous cell carcinoma (PeSCC) is a rare malignancy with limited treatment options in advanced stages. The phase II PERICLES trial (NCT03686332) investigated atezolizumab with or without radiotherapy in advanced penile cancer. Here, we report mature overall survival (OS) and updated progression-free survival (P...
T. Rafael, Alberto Gil-Jimenez, L. Elst et al.· Cancer immunology research· 0 citations
Relapsed or refractory lymphoma carries poor prognosis, with limited options after standard therapies. Spleen tyrosine kinase (SYK) mediates B-cell receptor and aberrant T-cell receptor signaling, promoting survival and proliferation. HMPL-523 (sovleplenib) is a novel, selective oral SYK inhibitor with preclinical acti...
P. Strati, D. Chraniuk, E. González Barca et al.· Blood Advances· 0 citations
Abstract Background To evaluate the effectiveness and safety of pembrolizumab plus axitinib as first-line therapy for metastatic renal cell carcinoma (mRCC) in a national real-world cohort. This study is the first from Panama and the first from Central America to address this treatment strategy. Methods We conducted a...
J. Pinto, A. Cárdenas· The Oncologist· 0 citations
Baseline Gustave Roussy Immune Score (GRIm) was the most consistent candidate prognostic marker in this real-world ES-SCLC cohort and was identified markedly shorter overall and progression-free survival.
David Sánchez García, Miguel Borregón-Rivilla, A. Moya-Martínez et al.· Cancer Management and Resear...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
